Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The company said the injury went away after the person ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

Pfizer is drawing healthcare attention as its obesity, oncology, vaccine, and medicine programs shape a broader pipeline ...

Pfizer returns to market focus after a finance leadership transition, prompting fresh discussion around valuation, pipeline ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Yet another experimental drug heavily touted by Pfizer Inc. has foundered in advanced testing, raising worries about productivity ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

A pill to treat obesity caused liver injury in a clinical trial Pfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity drugs are in ...